Attention-deficit hyperactivity disorder (ADHD) is a chronic condition and pharmacotherapy is the mainstay of treatment, with a variety of ADHD medications available to patients. However, it is unclear to what extent the long-term safety and efficacy of ADHD drugs have been evaluated prior to their market authorization. We aimed to quantify the number of participants studied and their length of exposure in ADHD drug trials prior to marketing.
We identified all ADHD medications approved by the Food and Drug Administration (FDA) and extracted data on clinical trials performed by the sponsor and used by the FDA to evaluate the drug’s clinical efficacy and safety. For each ADHD medication, we measured the total number of participants studied and the length of participant exposure and identified any FDA requests for post-marketing trials.
A total of 32 clinical trials were conducted for the approval of 20 ADHD drugs. The median number of participants studied per drug was 75 (IQR 0, 419). Eleven drugs (55%) were approved after <100 participants were studied and 14 (70%) after <300 participants. The median trial length prior to approval was 4 weeks (IQR 2, 9), with 5 (38%) drugs approved after participants were studied <4 weeks and 10 (77%) after <6 months. Six drugs were approved with requests for specific additional post-marketing trials, of which 2 were performed.
Clinical trials conducted for the approval of many ADHD drugs have not been designed to assess rare adverse events or long-term safety and efficacy. While post-marketing studies can fill in some of the gaps, better assurance is needed that the proper trials are conducted either before or after a new medication is approved.
Citation: Bourgeois FT, Kim JM, Mandl KD (2014) Premarket Safety and Efficacy Studies for ADHD Medications in Children. PLoS ONE 9(7): e102249. doi:10.1371/journal.pone.0102249
Editor: Harriet de Wit, University of Chicago, United States of America
Received: April 9, 2014; Accepted: June 16, 2014; Published: July 9, 2014
Copyright: © 2014 Bourgeois et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper or can be accessed via the FDA website (www.accessdata.fda.gov).
Funding: Drs. Bourgeois and Mandl were supported by a grant from the National Institute of Child Health and Human Development (1R21HD072382), National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
As many as 10% of children and adolescents in the United States carry a diagnosis of attention-deficit hyperactivity disorder (ADHD), making it one of the most common conditions of childhood. ,  The single most efficacious treatment for reducing symptoms of ADHD are medications and most children diagnosed with ADHD receive pharmacotherapy. , ,  Clinicians and patients have a large therapeutic armamentarium to choose from, with over a dozen ADHD medications marketed in a wide array of formulations and delivery systems .
The short-term therapeutic response to ADHD medications is upwards of 70%, among the highest of psychiatric medications. ,  As a result, although ADHD typically requires long-term treatment, the short-term efficacy of ADHD drugs can be assessed after a brief treatment period, often on the order of days to weeks .
Since most trials focus on efficacy measures as primary endpoints, clinical trials testing ADHD medications may be relatively short, resulting in drugs with limited long-term safety or efficacy data.  Further, since studies are powered to measure efficacy endpoints, sample sizes may be inadequate to detect rare adverse events related to ADHD medications .
Guidelines for the safety and efficacy evaluation of drugs are provided by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).  Though not binding, these requirements guide clinical trial practice by the United States Food and Drug Administration (FDA).  The ICH provides specific recommendations on the safety assessment of chronic drugs used in the treatment of non-life-threatening conditions, which includes ADHD.  The guideline states that since most adverse drug events first occur and are most frequent during the initial months of treatment, approximately 300 to 600 patients should be treated for at least 6 months prior to market availability. Some adverse events may increase in frequency or severity over time or may only occur after several months of treatment; therefore, at least 100 patients should be exposed to a drug for at least 12 months. And finally, the guidelines recommend that the total number of patients treated with a medicine prior to approval, including short-term exposure, should be about 1500.
To assess the extent to which rare adverse events and the long-term safety and efficacy of ADHD drugs have been evaluated prior to their market authorization, we sought to identify and evaluate all safety and efficacy trials submitted to the FDA for the approval of ADHD drugs and quantify the number of participants studied and their length of exposure prior to the market availability of each ADHD medicine. We hypothesized that the premarket study of many ADHD medications in children has been insufficient to adequately assess rare adverse events and long-term safety and efficacy.
Drugs Used in the Treatment of ADHD
We identified all drugs approved by the FDA for ADHD using information available on the FDA website as well as other online resources. ,  All products with a unique NDA number were selected. We recorded the drugs’ FDA approval date for the indication of ADHD, the approved ages for treatment, the drug formulation, the pharmaceutical company sponsoring the application, and the current marketing status of the drug. When there was no FDA approval date for ADHD, we used the date of the first label on which ADHD was listed as an indication for the drug (N = 2).
Data Sources and Extraction
For each drug identified, we obtained the FDA Drug Approval Package, which includes the medical and statistical reviews, approval letters, drug labels, and any related administrative documents and correspondence. For newer agents, these documents are posted on the FDA website.  When the approval packages were not available, they were obtained from the FDA through a Freedom of Information Act request.
We reviewed the approval documents and identified the clinical trials performed by the sponsor and used by the FDA to evaluate the drug’s clinical efficacy or safety in the review process. If the agent was not a New Molecular Entity (and thus prior trials and FDA review had been performed), we reviewed the clinical trials in the original FDA approval package in order to identify any pediatric patients who may have been studied in safety or efficacy assessments. Thus, for drugs representing new formulations or drugs repurposed for the indication of ADHD and for which the FDA approval process might be modified and possibly less stringent given the prior review, we analyzed all clinical trials that had been conducted for approval at any stage. Several drugs had FDA approvals that either recommended or required the conduct of additional, post-marketing clinical trials. When the approval packages did not include supplemental information on these trials, we searched the online trial registry ClinicalTrials.gov to determine whether additional trials had been performed. We also contacted the pharmaceutical companies who had sponsored the drug applications to inquire about clinical trials performed in response to the FDA requests.
For each medication we extracted the following information: number of clinical trials supporting the application, number of participants studied who received at least one dose of the study drug, participant age ranges, trial duration at dosage levels intended for clinical use (i.e. excluding open-label titration periods), and comparators (if any) employed. Trials were categorized as efficacy or safety trials, with safety trials defined as those explicitly labeled as safety by the sponsor.
The clinical trials related to the drug approvals were linked to publications in the medical literature with a search of PubMed. Trials and publications were matched on the drug name, trial design characteristics, number of participants, and trial duration .
Descriptive statistics were used to report the total number of participants studied for less than 6 months, for at least 6 months, and for at least 12 months. Since many drugs used in the treatment of ADHD have been on the market for many years and the FDA approval process may have evolved over this period, we also calculated these values for the drugs approved in the last 10 years (since 2004).
We identified 20 drugs approved by the FDA via a New Drug Application (NDA) for the treatment of ADHD in children (Table 1). These drugs represent 10 different active ingredients with the individual products differing based on the formulation and delivery systems. Most drugs were approved for children 6 years and older with two drugs approved for children as young as 3 years old. Only 3 of the drugs have been discontinued. Original drug approval packages were not available on the FDA website and therefore obtained via a Freedom of Information Act (FOIA) request for Ritalin, Ritalin SR, Desoxyn, Cylert, Dexedrine, Biphetamine, Adderall, and Adderall XR.
Table 1. Medications approved by the FDA for the treatment of ADHD.doi:10.1371/journal.pone.0102249.t001
Characteristics of Clinical Trials
There were 32 clinical trials conducted by sponsors prior to the initial FDA approval of the ADHD drugs. Of these, 5 studies–representing 3 drugs–were safety studies. The minimum age of participants in all of the trials was 6 years. Six of the drugs were studied in efficacy trials that included an active comparator (5 included both an active comparator and placebo) while all others were approved based on comparison to placebo alone. Among the 10 most recently approved drugs, only 2 included comparison to one of the ADHD drugs already marketed. A total of 8 (25%) of the trials have been published in the medical literature.
Number of Participants and Length of Study
The median number of participants studied per drug was 75 (IQR 0, 419; range 0 to 660). Overall, 2756 (66%) participants were studied for less than 6 months, 746 (18%) for 6 to 11 months, and 688 (16%) for 12 or more months (Table 2).
Table 2. Clinical trials conducted for the FDA approval of ADHD drugs in children.doi:10.1371/journal.pone.0102249.t002
Seven drugs were approved by the FDA for the treatment of ADHD without the submission of any clinical trial data by the sponsors. Of these, 5 were approved between 1943 and 1975, one (Adderall) in 1996 and another (Methylin) in 2003. Ritalin, the oldest drug approved for ADHD, was approved based on prior clinical experience, which was presented as a bibliography. Methylin was a new formulation of previously approved methylphenidate that underwent an NDA but without the submission of pediatric efficacy trials.  Desoxyn was originally approved in 1943 as an anorectic in the treatment of obesity but no clinical trials assessing its safety in children or its efficacy in the treatment of ADHD in children were identified in the original approval package. The indication for ADHD is first included on the drug label in 1965 without supporting clinical trials in the accompanying documentation. The approval package for Cylert includes information on pre-clinical trials without mention of clinical trials conducted for any indication. Dexedrine was approved for the treatment of narcolepsy, obesity, and ADHD, but the approval package does not include trials enrolling children or studying efficacy for ADHD. Similarly, Biphetamine was previously approved as an anorectic in adults, but the original approval package does not include safety assessments in children and ADHD was added as an indication in product labels starting in 1979 without supporting clinical trials. Adderall was originally approved in 1960 as an anorectic under the trade name Obetrol before being marketed without FDA approval as Adderall for the treatment of ADHD. Approval was subsequently obtained without clinical trials assessing its safety in children or efficacy in ADHD .
Among the 13 drugs with clinical trials studying ADHD, a total of 4 drugs (31%) were approved after less than 100 participants had been studied while 7 drugs (54%) were approved after study in less than 300 participants. Efficacy trials ranged from 1 to 10 weeks and safety trials from 6 to 12 months in length. The median trial length prior to approval was 4 weeks (IQR 2, 9; range 1 to 52 weeks), with 5 (38%) drugs approved after participants were studied for less than 4 weeks, 7 (54%) after less than 8 weeks, and 10 (77%) after less than 6 months.
Focusing on the 6 drugs approved since 2004, the median number of participants studied per drug was 259 (IQR 53, 517; range 45 to 629) and there were 1309 (74%), 127 (7%), and 327 (18%), participants studied for less than 6 months, 6 to 11 months, and 12 or more months of study, respectively. The median trial length prior to approval was 8 weeks (IQR 2, 20; range 1 to 52 weeks).
Based on the ICH guidelines for safety assessments of chronic medications, none of the drugs met the recommendation for 1500 participants studied prior to drug approval (Table 3). Three of the drugs, Daytrana, Focalin, and Concerta (15% of all ADHD drugs), met requirements to have at least 300 participants total exposed to the drug for 6 months prior to marketing. Daytrana and Focalin (10% of all ADHD drugs) were also compliant with the recommendation to study at least 100 participants for 12 months.
Table 3. Compliance of pre-approval ADHD clinical drug trials with ICH guidelines overall and during past 10 years.doi:10.1371/journal.pone.0102249.t003
Clinical Trials Requested by the FDA
FDA approval of 4 of the drugs included required submission of additional clinical trials by the sponsor and 2 drug approvals included recommendations for additional trials (Table 4). The basis for the required studies cited by the FDA included concerns over limited long-term safety data, limited study in the adolescent population, and insufficient information on specific potential adverse events –.
Table 4. Clinical trials recommended or required by the FDA at the time of drug approvala.doi:10.1371/journal.pone.0102249.t004
The sponsors for Daytrana and Kapvay conducted the required studies, adhering to the timelines imposed by the FDA for study completion. None of the studies required for Vyvanse or Intuniv or any of the studies recommended for Ritalin or Focalin XR could be identified. The corresponding pharmaceutical companies in each of these cases were contacted and were also not able to provide us with information that these trials had been conducted.
This is the first systematic assessment of patient exposure to ADHD medications prior to their approval and market availability. A total of 17 medications are currently available in the U.S. for the treatment of ADHD in children, 6 of which have been approved by the FDA in the last 10 years. These drugs are intended for chronic use in children, but the median trial length prior to approval is 4 weeks and only 3 of the drugs have been assessed in long-term safety trials. The number of exposed children prior to approval is also small, with 14 drugs approved after study in less than 300 participants. Concerta, Daytrana, and Focalin (15% of all ADHD drugs) are the only drugs that meet the ICH recommendations of at least 300 patients studied for 6 months prior to market availability.
Concerns over the lack of safety data–including adverse events and long-term safety issues–for ADHD drugs have been voiced by a number of entities, including the FDA, the NIH, and the European Committee for Medicinal Products for Human Use. , ,  Known adverse effects vary for the different drugs and include growth retardation, decreased appetite, insomnia, and cardiovascular effects. , – Post-marketing reports of adverse events prompted the FDA in 2007 to require manufacturers of drugs approved for the treatment of ADHD to develop Medication Guides with detailed information for clinicians and parents on possible adverse effects and precautions that can be taken to avoid them. ,  Package inserts of all stimulant drugs for the treatment of ADHD have also been amended to include warning language around specific risks. .
Because ADHD is a chronic condition, the long-term efficacy of ADHD drugs also warrants further consideration. ,  Long-term follow up studies of children treated with ADHD medications have not been designed to adequately assess the long-term benefits of medication therapy compared to behavioral interventions. ,  One prospective 8-year follow-up study of children with ADHD who had been treated for at least 14 months with medication indicated there may be no advantage in academic performance or social functioning in children who received medication compared to those managed with behavioral interventions.  Additional long-term studies are needed assessing the impact of ADHD treatments into adolescence and of outcome measures beyond ADHD symptoms that capture effects on long-term functioning.
In order for drugs to become available in a timely fashion, large long-term randomized controlled trials may not always be feasible. Instead, post-marketing observational trials can provide additional information on rare adverse events and better delineate a drug’s long-term safety and efficacy.  In the European Union, pharmaceutical companies seeking market authorization for a drug must submit a Risk Management Plan with detailed proposals for post-authorization pharmacovigilence activities and efficacy studies. ,  These management plans are considered continuous, evolving processes and can be modified at the request of regulatory agencies as new information–including safety concerns–become available , .
In the U.S., the FDA historically relied on studies referred to as “post-marketing commitments” to obtain additional safety and efficacy data after a drug was approved.  These commitments were agreed upon by the FDA and the pharmaceutical companies at the time of approval and were often mandated as a condition for approval. However, the FDA lacked any avenues for enforcement, and reports showed that as many as two-thirds of requested studies were never started by the pharmaceutical companies. ,  The FDA Amendments Act of 2007 granted the FDA additional authority to require post-marketing studies–now referred to as “post-marketing requirements”–and also expanded the conditions under which the FDA could make the requests.  The FDA may now take enforcement action to ensure studies are conducted and recent reports have shown substantial improvement in compliance with study requests .
While we found poor compliance with post-marketing study requests for ADHD drugs, moving forward, these studies may represent an important tool for the detection of rare adverse events and the long-term safety and efficacy of medications. However, observational studies are not equivalent to randomized controlled trials powered to detect adverse events or specific efficacy end-points, nor can they approximate the rigor of randomized trials in accounting for treatment selection bias and other design issues.  Instead, post-marketing observational studies should complement pre-approval clinical trials, designed to include sufficient patient exposure to reasonably assess specific long-term safety and efficacy measures. As such, it is critical that we re-evaluate current standards in pre-approval trials and the exposure of patients to a new drug prior to its approval .
Three-arm trials, including the experimental drug, an active reference treatment, and a placebo comparator, are recommended by the ICH and by the European Medicines Agency specifically for the clinical investigation of ADHD drugs. ,  Three-arm trials serve two main purposes. First, the placebo comparator provides internal trial validation and demonstrates superiority of both drugs to the placebo control. Secondly, comparison of the new drug to an acknowledged standard yields comparative data on the safety and efficacy profiles of new drugs to other agents already available. We identified only 6 ADHD drugs that had been studied in comparison to another drug, indicating that ADHD drugs are introduced to the market with very little comparative data to guide clinicians on the new drug’s effectiveness in the context of all available options.
One of the limitations of this study is that, in some instances, the records from the FDA may have been incomplete. For each of the drugs, however, we were able to obtain the original approval packages. Given that many of these agents have been on the market for decades, there may be additional safety and efficacy information that has emerged in studies conducted after the original FDA approval. Nonetheless, our findings reflect the studies required in the FDA approval process, including the trials for a number of recently approved medications. Finally, our study was limited to ADHD drugs and additional study is needed to determine whether the FDA approval process is similar for other drug classes used in pediatric patients.
In conclusion, clinical trials conducted for the approval of many ADHD drugs have not been designed to assess rare adverse events or long-term safety and efficacy. Despite the large number of available drugs, comparative effectiveness trials are rare. While post-marketing studies can fill in some of the gaps, FDA enforcement is important to ensure that post-market surveillance studies are completed. An ambitious agenda to assess long-term outcomes in the millions of patients on these medications is warranted.
Conceived and designed the experiments: FB KM. Analyzed the data: FB JK KM. Contributed to the writing of the manuscript: FB JK KM.
- 1. Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, et al.. (2014) Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003–2011. J Am Acad Child Adolesc Psychiatry 53: 34–46 e32.
- 2. Voort JLV, He J-P, Jameson ND, Merikangas KR (2014) Impact of the DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD) Age of Onset Criterion in the U.S. Adolescent Population. Journal of the AMerican Academy of Child & Adolescent Psychiatry In Press.
- 3. Visser SN, Lesesne CA, Perou R (2007) National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics 119 Suppl 1S99–106. doi: 10.1542/peds.2006-2089o
- 4. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 56: 1073–1086. doi: 10.1001/archpsyc.56.12.1073
- 5. Manos MJ, Tom-Revzon C, Bukstein OG, Crismon ML (2007) Changes and challenges: managing ADHD in a fast-paced world. J Manag Care Pharm 13: S2–S13; quiz S14–S16.
- 6. May DE, Kratochvil CJ (2010) Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs 70: 15–40. doi: 10.2165/11530540-000000000-00000
- 7. Wigal SB (2009) Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 23 Suppl 121–31. doi: 10.2165/00023210-200923000-00004
- 8. Huang YS, Tsai MH (2011) Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge. CNS Drugs 25: 539–554. doi: 10.2165/11589380-000000000-00000
- 9. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Guidelines. Available: http://www.ich.org/products/guidelines. Accessed 2013 Oct 8.
- 10. U.S. Department of Health and Human Services. FDA Regulatory Information. Available: http://www.fda.gov/RegulatoryInformation/Guidances/ucm122049.htm. Accessed 2013 Oct 8.
- 11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1994) ICH Harmonised Tripartite Guideline: The extent of population exposure to assesss clincial safety for drugs intended for long-term treatment of non-life-threatening conditions–E1. Available: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E1/Step4/E1_Guideline.pdf. Accessed 2013 Oct 8.
- 12. National Institutes of Health (National Institute of Mental Health). Available: http://www.nimh.nih.gov. Accessed 2013 Oct 8.
- 13. U.S. Department of Health and Human Services Drugs@FDA. Available: http://www.accessdata.fda.gov.Accessed O2013 Oct 8.
- 14. Bourgeois FT, Murthy S, Mandl KD (2010) Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 153: 158–166. doi: 10.7326/0003-4819-153-3-201008030-00006
- 15. U.S. Food and Drug Administration: Center for drug evaluation and research (2002) Drug Approval Package: Methylin. Available: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-419_Methylin.cfm. Accessed 2013 Dec 1.
- 16. U.S. Food and Drug Administration: Center for drug evaluation and research (1996) Approval letter: Adderall. Available: http://www.accessdata.fda.gov/drugsatfda_docs/nda/96/11522S010_Adderall.pdf. Accessed 2013 Dec 1.
- 17. U.S. Food and Drug Administration: Center for drug evaluation and research (2004) Medical Reveiw: Focalin XR. Available: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021802s000_MedR.pdf. Accessed 2013 Oct 8.
- 18. U.S. Food and Drug Administration: Center for drug evaluation and research (2007) Medical Review: Vyvanse. Available: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021977s000_MedR.pdf. Accessed 2013 Oct 8.
- 19. U.S. Food and Drug Administration: Center for drug evaluation and research (2010) Supplement Approval: Kapvay. Available: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022331s001, s002ltr.pdf. Accessed 2013 Oct 8.
- 20. European Medicines Agency: Committee for Medicinal Products for Human use (2008) Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD). Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/08/WC500095686.pdf. Accessed 2013 Oct 8.
- 21. NIH Consensus Development Program (1998) Diagnosis and treatment of attention deficit hyperactivity disorder. National Institutes of Health Consensus Development Conference Statement.
- 22. Dopheide JA, Pliszka SR (2009) Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy 29: 656–679. doi: 10.1592/phco.29.6.656
- 23. Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, et al. (2007) Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 46: 1015–1027. doi: 10.1097/chi.0b013e3180686d7e
- 24. Warikoo N, Faraone SV (2013) Background, clinical features and treatment of attention deficit hyperactivity disorder in children. Expert Opin Pharmacother.
- 25. U.S. Food and Drug Administration. FDA Asks Attention-Deficit Hyperactivity Disorder (ADHD) Drug Manufacturers to Develop Patient Medication Guides. Available: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm107918.htm. Accessed 2013 Oct 8.
- 26. U.S. Food and Drug Administration (2007) FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events. FDA News. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108849.htm. Accessed 2013 Oct 8.
- 27. Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, et al. (2007) 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 46: 989–1002. doi: 10.1097/chi.0b013e3180686d48
- 28. Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, et al. (2009) The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 48: 484–500. doi: 10.1097/chi.0b013e31819c23d0
- 29. Golder S, Loke YK, Bland M (2011) Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 8: e1001026. doi: 10.1371/journal.pmed.1001026
- 30. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, et al. (2001) Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107: E105. doi: 10.1542/peds.107.6.e105
- 31. European Medicines Agency (2012) Guideline on good pharmacovigilance practices (GVP): Module V- Risk management systems. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf. Accessed 2013 Oct 8.
- 32. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2004) Pharmacovigilence planning–E2E. Available: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2E/Step4/E2E_Guideline.pdf. Accessed 2013 Oct 8.
- 33. Raine J, Wise L, Blackburn S, Eichler HG, Breckenridge A (2011) European perspective on risk management and drug safety. Clin Pharmacol Ther 89: 650–654. doi: 10.1038/clpt.2011.28
- 34. U.S. Food and Drug Administration (2011) Guidance for Industry: Postmarketing studies and Clincial Trials–Implementation of section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM172001.pdf. Accessed 2013 Oct 8.
- 35. Avorn J (2006) Evaluating drug effects in the post-Vioxx world: there must be a better way. Circulation 113: 2173–2176. doi: 10.1161/circulationaha.106.625749
- 36. Avorn J (2007) Paying for drug approvals–who’s using whom? N Engl J Med 356: 1697–1700. doi: 10.1056/nejmp078041
- 37. U.S. Food and Drug Administration Amendments Act of 2007 (2007) Public Law No.105–185.
- 38. U.S. Food and Drug Administration (2012) Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments. Federal Register 77: 13339–13343.
- 39. Thomas L, Peterson ED (2012) The value of statistical analysis plans in observational research: defining high-quality research from the start. JAMA 308: 773–774. doi: 10.1001/jama.2012.9502
- 40. Duijnhoven RG, Straus SM, Raine JM, de Boer A, Hoes AW, et al. (2013) Number of patients studied prior to approval of new medicines: a database analysis. PLoS Med 10: e1001407. doi: 10.1371/journal.pmed.1001407
- 41. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2001) ICH Topic E10: Choice of control group in clinical trials. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002925.pdf. Accessed 2013 Oct 8.
- 42. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, et al. (2001) Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108: 883–892. doi: 10.1542/peds.108.4.883
- 43. Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, et al. (2005) ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 44: 1015–1023. doi: 10.1097/01.chi.0000173291.28688.e7
- 44. Findling RL, Turnbow J, Burnside J, Melmed R, Civil R, et al. (2010) A randomized, double-blind, multicenter, parallel-group, placebo-controlled, dose-optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. CNS Spectr 15: 419–430.
- 45. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, et al. (2007) Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 62: 970–976. doi: 10.1016/j.biopsych.2007.04.015
- 46. Jain R, Babcock T, Burtea T, Dirks B, Adeyi B, et al. (2011) Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. Child Adolesc Psychiatry Ment Health 5: 35. doi: 10.1186/1753-2000-5-35
- 47. Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, et al. (2008) A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121: e73–84. doi: 10.1542/peds.2006-3695
- 48. Jain R, Segal S, Kollins SH, Khayrallah M (2011) Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 50: 171–179. doi: 10.1016/j.jaac.2010.11.005
- 49. Findling RL, Katic A, Rubin R, Moon E, Civil R, et al. (2010) A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 20: 365–375. doi: 10.1089/cap.2009.0122